Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of eplontersen for long-term safety in transthyretin amyloid cardiomyopathy
MOH_2023-02-14_012355Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eplontersen in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Ionis Pharmaceuticals. Started Jan 2023; status: recruiting.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on MOH_2023-02-14_012355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-14_012355.